Clinical Trial Update: Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens [Phase 2]

View source ↗

Summary

Phase 2 study evaluating subcutaneous bortezomib regimens in relapsed/refractory multiple myeloma after prior IV bortezomib; the trial was terminated and result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Velcade (bortezomib)

Snippet

Sponsor: Oncotherapeutics | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2017-01-16